OUTCOMES FROM OUTPATIENT TREATMENT OF COVID-19 WITH MONOCLONAL ANTIBODY THERAPY: A STATEWIDE SURVEY
Introduction: Over 500,000 people have died from COVID-19 in the U.S. Few treatments are available beyond supportive care. Three neutralizing monoclonal antibody (mAb) therapies have been authorized by the U.S. Food and Drug Administration for emergency use to treat mild to moderate COVID-19 in high-risk patients. There is little evidence for their safety and efficacy.
Purpose: Describe clinical outcomes among patients receiving mAb therapy for COVID-19 in Michigan.
Methods: Brief telephone scripted interviews were conducted by medical and pharmacy students from WMed and Ferris State University, respectively. Telephone numbers of mAb patients were obtained from the Michigan Department of Health and Human Services (MDHHS). Patients from long-term care facilities were excluded. Data were entered into an electronic database (REDCap) and basic statistical analyses performed. This study was approved by the MDHHS IRB.
Results: Of 472 mAb therapy recipients called, 327 (69%) answered the call. 291 (62%) agreed to be interviewed. 137 (47%) respondents were male. The median age was 65 (IQR 57-72). 11 (3.9%) respondents were hospitalized within 14 days of mAb therapy, median length of stay 4.25 days (IQR 2.25-9.75). 184 (63%) respondents reported feeling better two days after mAb infusions, and 247 (85%) reported feeling 'considerably better' at the time they were interviewed. No deaths were identified.
Conclusion: In one of the first reports outside of clinical trials, we describe low hospitalization rates and good clinical improvement following mAb therapy in high-risk patients with COVID-19 who received mAb therapy. These results are consistent with the limited published evidence.